Mazdutide FAQ: common questions answered
A weekly dual-hormone injection approved in China, with phase 3 weight-loss results.
Also called: IBI362, IBI-362, LY3305677, LY-3305677, Xinermei.
GLP-1 / glucagon dual agonists · GLP-1 and glucagon receptor dual agonist · Evidence: Approved drug.
- Is Mazdutide FDA-approved? No FDA approval or dosing label found. China approved adult weight management in June 2025 and diabetes in September 2025; these are not US approvals.
- How do people take it? Under the skin, once weekly. 48 weeks. Source: studied in a trial.
- What's the difference between Mazdutide and Tirzepatide? Mazdutide: a weekly dual-hormone injection approved in China, with phase 3 weight-loss results. Tirzepatide: a weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects. Why people pair them: people seek a glucagon effect alongside appetite control.
- Can I take it with Tirzepatide? People seek a glucagon effect alongside appetite control. Overlapping GLP-1 effects; no trial validates the home combination. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? It is unclear (WADA 2026). China approval means S0 is not automatic. No named listing found; obtain an authoritative sport-specific ruling.
- How long does a mixed vial last? No validated home-mixed stability or beyond-use time was found.
Related to Mazdutide
- Survodutide: A weekly dual-hormone injection with phase 3 weight-loss data and frequent stomach side effects.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA · FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- The Prohibited List, World Anti-Doping Agency · World Anti-Doping Agency · 2026
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products, Therapeutic Goods Administration · Therapeutic Goods Administration · 2026
- WEGOVY- semaglutide injection, solution WEGOVY- semaglutide tablet, DailyMed · DailyMed · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society., Mozaffarian D et al. · The American journal of clinical nutrition · 2025
- Weight loss medicine Mazdutide approved for commercialization in China, Shanghai Municipal Government · Shanghai Municipal Government · 2025
- Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration · TGA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.